Previous studies have confirmed that the active estrogens converted from adrenal DHEA prevent NAFLD only by precisely activating G protein-coupled estrogen receptor (GPER1, also called GRP30) but not ESR1 or ESR2 within the liver organ [14]. Here, ESR2 is linked to metabolic dysfunction-associated steatotic liver disease.